Systemic Treatment Options for Generalized Lichen Planus | NCT06739551 | Trialant

Systemic Treatment Options for Generalized Lichen Planus | NCT06739551 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Oral methotrexate group (Group A)	Active Comparator	Patients with generalized lichen planus will be given 10 mg per week	Drug: Methotrexate (drug)
Oral Acitretin group (Group B)	Active Comparator	Patients with generalized lichen planus will be given oral acitretin 50 mg once daily	Drug: Acitretin

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Efficacy of oral methotrexate vs. oral acitretin in the treatment of generalized lichen planus	Efficacy will be assesssed clinically at each follow up visit. Final efficacy of each treatment will be determined at last follow up visit( i.e. at 12 th week after start of treatment).The final efficacy will be divided into following groups on the basis of clinical resolution of disease: Remission: It is defined as complete resolution of all lesions leaving behind normal skin or post inflammatory pigmentation. Improvement: It is defined as a more than 50% decrease of the disease, as clinically measured by the surface area from the baseline. No improvement: It is defined as less than a 50% improvement in the disease, as measured clinically by the surface area from the baseline.	Clinical assessment for efficacy will be done 4 weekly for 12 weeks.

Contacts/Locations Module

Condition Browse Module

Intervention Browse Module